The emerging role of immunotherapy in advanced urothelial cancers
Authors:
- 1 May 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 30 (3) , 172-180
Abstract
Purpose of review: Recent Food and Drug Administration (FDA) approval of five new immune checkpoint inhibitors for the treatment of metastatic urothelial cancer represents the first major treatment breakthrough for this disease since the introduction of combination chemotherapy over 30 years ago. This review examines the recent clinical trials leading to FDA approval of these agents, the current challenges facing immunotherapy and areas that require further research. Recent findings: The programmed death 1 receptor (PD-1) and its ligand programmed death ligand-1 (PD-L1) are important negative regulators of immune activity, preventing destruction of normal tissues and autoimmunity. Aggressive bladder cancer cells express aberrantly high levels of PD-L1, hijacking the normal immune-regulatory pathway to evade detection and destruction by the immune system. Blockade of the PD-1/PD-L1 axis with immune checkpoint inhibitors augments the immune system's ability to eradicate bladder cancer with impressive safety and tolerability profiles. Summary: Recent clinical trials demonstrate that patients with metastatic urothelial carcinoma are responsive to immune checkpoint inhibitor therapy. Optimal treatment regimens are still under development, but activity has been demonstrated in both the first and second-line setting for metastatic disease.Keywords
This publication has 47 references indexed in Scilit:
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with SurvivalClinical Cancer Research, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- PD‐L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine bindingEuropean Journal of Immunology, 2007
- Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinomaInvestigational New Drugs, 2006
- PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2European Journal of Immunology, 2002
- Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient MiceScience, 2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996